New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer

  • Romain Cohen
  • Magali Svrcek
  • Chantal Dreyer
  • Pascale Cervera
  • Alex Duval
  • Marc Pocard
  • Jean-François Fléjou
  • Aimery de Gramont
  • Thierry AndréEmail author
Gastrointestinal Cancers (J Meyer, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Gastrointestinal Cancers


Recently, colorectal cancer (CRC) subtyping consortium identified four consensus molecular subtypes (CMS1–4). CMS1 is enriched for deficient mismatch repair (dMMR) and BRAF V600E tumors. Intriguingly, this subtype has better relapse-free survival but worse overall survival after relapse compared with the other subtypes. Growing evidence is accumulating on the benefit of specific therapeutic strategies such as immune checkpoint inhibition therapy in dMMR tumors and mitogen-activated protein kinase (MAPK) pathway targeted therapy in tumors harboring BRAF V600E mutation. After reviewing dMMR prognostic value, immune checkpoints as major targets for dMMR carcinomas will be highlighted. Following, BRAF V600E prognostic impact will be reviewed and therapeutic strategies with the combination of cytotoxic agents and especially the combinations of BRAF and MAPK inhibitors will be discussed.


Microsatellite instability BRAF mutation Immune checkpoint PD-1 PD-L1 



Authors would like to thank Magdalena Benetkiewicz for reviewing/editorial assistance.

Compliance with Ethical Standards

Conflict of Interest

Romain Cohen declares that he has no conflict of interest.

Magali Svrcek declares that she has no conflict of interest.

Chantal Dreyer declares that she has no conflict of interest.

Pascale Cervera declares that he has no conflict of interest.

Alex Duval declares that he has no conflict of interest.

Marc Pocard declares that he has no conflict of interest.

Jean-François Fléjou declares that he has no conflict of interest.

Aimery de Gramont has received compensation from Roche for service on advisory boards and from Sanofi for the attendance of meetings.

Thierry André is principal investigator for studies in metastatic colorectal cancer sponsored by Bristol-Myers Squibb, Novartis, and Roche and has received compensation from Roche, Amgen, and Bristol-Myers Squibb for service as a consultant.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance•• Of outstanding importance

  1. 1.
    Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50:113–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Dienstmann R, Guinney J, Delorenzi M, Reynies AD, Roepman P, Sadanandam A, et al. Colorectal cancer subtyping consortium (CRCSC) identification of a consensus of molecular subtypes. J Clin Oncol. 2014;32(5s). Suppl; abstr 3511.Google Scholar
  3. 3.
    Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. Kemp C, editor. PLoS Med. 2013;10:e1001453.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.••
    Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20. MMR deficiency predicts efficacy of immune checkpoint inhibition with PD-1 inhibitor pembrolizumab in colorectal and non-colorectal carcinomas. CrossRefPubMedGoogle Scholar
  5. 5.
    Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni M, Capozzi E, et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol. 1999;154:1805–13.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–26.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29:1261–70.CrossRefPubMedGoogle Scholar
  9. 9.
    Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. JNCI J Natl Cancer Inst. 2011;103:863–75.CrossRefPubMedGoogle Scholar
  10. 10.
    Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A, et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol. 2010;21:772–80.CrossRefPubMedGoogle Scholar
  11. 11.
    Tougeron D, Sickersen G, Lecomte T, Mouillet G, Trouilloud I, Coriat R, et al. Impact of adjuvant chemotherapy with 5-FU or FOLFOX in colon cancers with microsatellite instability: an AGEO multicenter study. J Clin Oncol. 2014;32:5s. Suppl; abstr 3508.CrossRefGoogle Scholar
  12. 12.
    Collura A, Lagrange A, Svrcek M, Marisa L, Buhard O, Guilloux A, et al. Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil-based chemotherapy. Gastroenterology. 2014;146:401–11.CrossRefPubMedGoogle Scholar
  13. 13.
    Dorard C, de Thonel A, Collura A, Marisa L, Svrcek M, Lagrange A, et al. Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nat Med. 2011;17:1283–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Colas C, Coulet F, Svrcek M, Collura A, Fléjou J-F, Duval A, et al. Lynch or not Lynch? Is that always a question? Adv Cancer Res. 2012;113:121–66.CrossRefPubMedGoogle Scholar
  15. 15.
    Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008;10:293–300.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352:1851–60.CrossRefPubMedGoogle Scholar
  17. 17.
    Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248–57.PubMedGoogle Scholar
  18. 18.
    Umar A, Boland CR, Terdiman JP, Chapelle A d l, Ruschoff J, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. JNCI J Natl Cancer Inst. 2004;96:261–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Brueckl WM, Moesch C, Brabletz T, Koebnick C, Riedel C, Jung A, et al. Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res. 2003;23:1773–7.PubMedGoogle Scholar
  20. 20.
    Des Guetz G, Mariani P, Cucherousset J, Benamoun M, Lagorce C, Sastre X, et al. Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res. 2007;27:2715–9.PubMedGoogle Scholar
  21. 21.
    Koopman M, Kortman GAM, Mekenkamp L, Ligtenberg MJL, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100:266–73.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Tran B, Kopetz S, Tie J, Gibbs P, Jiang Z-Q, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117:4623–32.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.••
    Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20:5322–30. In metastatic colorectal cancer, both MMR deficiency and BRAFV600E mutation confer poor prognosis. The poor prognosis of dMMR seens to be driven by BRAFV600E. CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Smith CG, Fisher D, Claes B, Maughan TS, Idziaszczyk S, Peuteman G, et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy cetuximab. Clin Cancer Res. 2013;19:4104–13.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Donnard E, Asprino PF, Correa BR, Bettoni F, Koyama FC, Navarro FC, et al. Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy. Oncotarget. 2014;5:9199.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Giannakis M, Shukla S, Mu J, Nishihara R, Yamauchi M, Sukawa Y, et al. Comprehensive molecular characterization of colorectal cancer reveals genomic predictors of immune cell infiltrates. J Clin Oncol. 2015;33. Suppl; abstr 3505.Google Scholar
  27. 27.
    Maby P, Tougeron D, Hamieh M, Mlecnik B, Kora H, Bindea G, et al. Correlation between density of CD8+ T cell infiltrates in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy. Cancer Res. Published Online First June 9, 2015.Google Scholar
  28. 28.
    Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.CrossRefPubMedGoogle Scholar
  29. 29.
    Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66.CrossRefPubMedGoogle Scholar
  30. 30.
    Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2010;138:1429–40.CrossRefPubMedGoogle Scholar
  31. 31.
    Lal N, Beggs AD, Willcox BE, Middleton GW. An immunogenomic stratification of colorectal cancer: implications for development of targeted immunotherapy. OncoImmunology. 2015;4:e976052.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.•
    Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43–51. Colorectal cancers with MMR deficiency specifically upregulate several immune checkpoints, unlike tumors with proficient MMR system. CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Bodo S, Colas C, Buhard O, Collura A, Tinat J, Lavoine N, et al. Diagnosis of constitutional mismatch repair-deficiency syndrome based on microsatellite instability and lymphocyte tolerance to methylating agents. Gastroenterology. Published Online First June 25, 2015.Google Scholar
  34. 34.
    Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934.CrossRefPubMedGoogle Scholar
  35. 35.
    Capper D, Voigt A, Bozukova G, Ahadova A, Kickingereder P, von Deimling A, et al. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer: BRAF V600E immunohistochemistry in MSI-H colorectal cancer. Int J Cancer. 2013;133:1624–30.CrossRefPubMedGoogle Scholar
  36. 36.
    Cremolini C, Bartolomeo MD, Amatu A, Antoniotti C, Moretto R, Berenato R, et al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann Oncol. 2015; Published Online First July 7, 2015.Google Scholar
  37. 37.
    Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28:466–74.CrossRefPubMedGoogle Scholar
  38. 38.
    André T, de Gramont A, Chibaudel B, Tijeras-Raballand A, Duval A, Hickish T, et al. MOSAIC study: actualization of overall survival (OS) with 10 years follow up and evaluation of BRAF. By GERCOR and MOSAIC investigators. Ann Oncol. 2014;25(4):iv167–209.CrossRefGoogle Scholar
  39. 39.
    Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem J-L, et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:862–73.CrossRefPubMedGoogle Scholar
  40. 40.
    Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, et al. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/alliance N0147. JNCI J Natl Cancer Inst. 2014;106:dju106.CrossRefPubMedGoogle Scholar
  41. 41.
    French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res. 2008;14:3408–15.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY, Yothers G, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012;18:6531–41.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Taieb J, Le Malicot K, Penault-Llorca F, Bouche O, Shi Q, Thibodeau S, et al. Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/− cetuximab: a pooled analysis of 3934 pts from the PETACC8 and N0147 trials. J Clin Oncol. 2015;33 (suppl; abstr 3507).Google Scholar
  44. 44.
    Van Cutsem E, Köhne C-H, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. JCO. 2011;29:2011–9.CrossRefGoogle Scholar
  45. 45.
    Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023–34.CrossRefPubMedGoogle Scholar
  46. 46.
    Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S-E, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–75.CrossRefPubMedGoogle Scholar
  47. 47.
    Stintzing S, Jung A, Rossius L, Modest DP, Fischer von Weikersthal L, Decker T, et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Eur Cancer Congress. 2013;Abstract 17.Google Scholar
  48. 48.
    Peeters M, Price TJ, Cervantes Ruiperez A, Sobrero A, Ducreux M, André T, et al. Impact of baseline covariates and prior therapy on the efficacy of second-line panitumumab (pmab) + FOLFIRI vs FOLFIRI treatment. Ann Oncol. 2014;25(4):iv167–209.Google Scholar
  49. 49.
    André T, Blons H, Mabro M, Chibaudel B, Bachet J-B, Tournigand C, et al. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol. 2013;24:412–9.CrossRefPubMedGoogle Scholar
  50. 50.
    De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753–62.CrossRefPubMedGoogle Scholar
  51. 51.
    Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. lancet Oncol. 2013;14:749–59.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O’Callaghan CJ, Marginean C, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer—results from NCIC CTG/AGITG CO.17. Clin Cancer Res. 2014;20:744–53.CrossRefPubMedGoogle Scholar
  53. 53.•
    Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;112:1888-94. In this meta-analysis, the hazard ratio for OS benefit with anti-EGFR monoclonal antibodies was 0.97 (95% CI; 0.67–1.41) for BRAF V600E tumors whereas the hazard ratio was 0.81 (95% CI; 0.70–0.95) for RAS WT /BRAF WT mCRC. However the test of interaction was not statistically significant. Thus there is insufficient data to justify the exclusion of anti-EGFR therapies for patients with RAS WT /BRAF V600E mCRC.Google Scholar
  54. 54.
    Seligmann J, Fisher D, Elliott F, Richman S, Butler R, Cheadle J, et al. Exploring the poor outcomes of BRAF mutant (BRAF mut) advanced colorectal cancer (aCRC): analysis from 2,530 patients (pts) in randomized clinical trials (RCTs). J Clin Oncol. 2015;33 (suppl; abstr 3509).Google Scholar
  55. 55.
    Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol. 2010;11:845–52.CrossRefPubMedGoogle Scholar
  56. 56.
    Salvatore L, Loupakis F, Cremolini C, Schirripa M, Masi G, Antoniotti C, et al. FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients. J Clin Oncol. 2012;30 suppl; abstr 3585.Google Scholar
  57. 57.
    Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609–18.CrossRefPubMedGoogle Scholar
  58. 58.
    Loupakis F, Cremolini C, Lonardi S, Tomasello G, Ronzoni M, Zaniboni A, et al. Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study. J Clin Oncol. 2014;32:5s (suppl; abstr 3519).Google Scholar
  59. 59.•
    Loupakis F, Cremolini C, Antoniotti C, Lonardi S, Ronzoni M, Zaniboni A, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): updated survival results and final molecular subgroups analyses. J Clin Oncol. 2015;33 (suppl; abstr 3510). Compared with FOLFIRI/bevacizumab, FOLFOXIRI/bevacizumab is associated with a non-significant increase of overall survival for patients with BRAFV600E metastatic colorectal cancers (19 months versus 10.7 months; HR 0.54, 95% CI 0.24–1.20). Google Scholar
  60. 60.
    Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–65.CrossRefPubMedGoogle Scholar
  62. 62.
    Kopetz S, Desai J, Chan E, Hecht JR, O’Dwyer PJ, Lee RJ, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol. 2010;28:15s (suppl; abstr 3534).Google Scholar
  63. 63.••
    Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100–3. In colorectal cancer, BRAFV600E inhibition induces a feedback activation of EGFR. The combination of vemurafenib with an anti-EGFR therapy or a MEK inhibitor may be an effective way to overpass BRAF inhibitor primary resistance in BRAF V600E metastatic CRC . Google Scholar
  64. 64.
    Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9.CrossRefPubMedGoogle Scholar
  65. 65.
    Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386:444–51.CrossRefPubMedGoogle Scholar
  66. 66.
    Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464:427–30.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464:431–5.CrossRefPubMedGoogle Scholar
  68. 68.
    Tabernero J, Chan E, Baselga J, Blay J-Y, Chau I, Hyman DM, et al. VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). J Clin Oncol. 2014;32:5s. Suppl; abstr 3518.CrossRefGoogle Scholar
  69. 69.
    Yaeger R, Cercek A, O’Reilly EM, Reidy DL, Kemeny N, Wolinsky T, et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res. 2015;21:1313–20.CrossRefPubMedGoogle Scholar
  70. 70.
    Hong D, Morris V, Osta B El, Fu S, Overman M, Piha-Paul S, et al. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. J Clin Oncol. 2015;33 (suppl; abstr 3511).Google Scholar
  71. 71.
    Corcoran RB, Atreya CE, Falchook GS, Infante JR, Hamid O, Messersmith WA, et al. Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): updated efficacy and biomarker analysis. J Clin Oncol. 2014;32(5s). Suppl; abstr 3517.Google Scholar
  72. 72.
    Atreya C, Van Cutsem E, Bendell J, Andre T, Schellens J, Gordon M, et al. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). J Clin Oncol. 2015;(suppl; abstr 103).Google Scholar
  73. 73.
    Gomez-Roca CA, Delord J, Robert C, Hidalgo M, von Moos R, Arance A, et al. Encorafenib (LGX818), an oral BRAF inhibitor, in patients (pts) with BRAF V600E metastatic colorectal cancer (mCRC): results of dose expansion in an open-label, phase 1 study. Ann Oncol. 2014;25:iv182–3.CrossRefGoogle Scholar
  74. 74.
    Drug combo beneficial in colorectal cancer. Cancer Discov. 2015;5:102–102.Google Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Romain Cohen
    • 1
  • Magali Svrcek
    • 2
    • 3
  • Chantal Dreyer
    • 1
  • Pascale Cervera
    • 2
    • 3
  • Alex Duval
    • 4
  • Marc Pocard
    • 5
    • 6
  • Jean-François Fléjou
    • 2
    • 3
  • Aimery de Gramont
    • 5
    • 7
  • Thierry André
    • 1
    • 3
    • 4
    • 5
    Email author
  1. 1.Department of Medical OncologyHospital Saint-Antoine, Assistance publique-Hôpitaux de ParisParisFrance
  2. 2.Department of PathologyHospital Saint-Antoine, APHPParisFrance
  3. 3.University Pierre et Marie Curie (UMPC)ParisFrance
  4. 4.INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-AntoineEquipe “Instabilité des Microsatellites et Cancers,” Equipe labellisée par la Ligue Nationale contre le CancerParisFrance
  5. 5.GERCOR, Oncology Multidisciplinary GroupParisFrance
  6. 6.Departement of Digestive and Oncologic SurgeryHospital Lariboisière, APHPParisFrance
  7. 7.Department of Medical OncologyInstitut Hospitalier Franco-BritanniqueLevallois-PerretFrance

Personalised recommendations